GLP1R and type 2 diabetes mellitus: A recent study highlights the substantial benefits of triple therapy combining SGLT2is, finerenone, and GLP1 RAs in patients with T2DM and a urinary albumin-to-creatine ratio (UACR) ≥ 30 mg/g.